Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

YARS2 Antikörper (C-Term)

Dieses Kaninchen Polyklonal-Antikörper erkennt spezifisch YARS2 in WB und IHC (p). Er zeigt eine Reaktivität gegenüber Human und wurde in 3+ Publikationen erwähnt.
Produktnummer ABIN1882153

Kurzübersicht für YARS2 Antikörper (C-Term) (ABIN1882153)

Target

Alle YARS2 Antikörper anzeigen
YARS2 (Tyrosyl-tRNA Synthetase 2, Mitochondrial (YARS2))

Reaktivität

  • 24
  • 13
  • 5
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
Human

Wirt

  • 25
  • 1
Kaninchen

Klonalität

  • 26
Polyklonal

Konjugat

  • 19
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Dieser YARS2 Antikörper ist unkonjugiert

Applikation

  • 18
  • 9
  • 6
  • 4
  • 4
  • 4
  • 3
Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Klon

RB14936
  • Bindungsspezifität

    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 399-427, C-Term

    Homologie

    M, Rat

    Aufreinigung

    This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

    Immunogen

    This YARS2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 399-427 amino acids from the C-terminal region of human YARS2.

    Isotyp

    Ig Fraction
  • Applikationshinweise

    WB: 1:1000. IHC-P: 1:10~50

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Liquid

    Buffer

    Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

    Konservierungsmittel

    Sodium azide

    Vorsichtsmaßnahmen

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Lagerung

    4 °C,-20 °C

    Haltbarkeit

    6 months
  • Riley, Menezes, Rudinger-Thirion, Duff, de Lonlay, Rotig, Tchan, Davis, Cooper, Christodoulou: "Phenotypic variability and identification of novel YARS2 mutations in YARS2 mitochondrial myopathy, lactic acidosis and sideroblastic anaemia." in: Orphanet journal of rare diseases, Vol. 8, pp. 193, (2014) (PubMed).

    Riley, Cooper, Hickey, Rudinger-Thirion, McKenzie, Compton, Lim, Thorburn, Ryan, Giegé, Bahlo, Christodoulou: "Mutation of the mitochondrial tyrosyl-tRNA synthetase gene, YARS2, causes myopathy, lactic acidosis, and sideroblastic anemia--MLASA syndrome." in: American journal of human genetics, Vol. 87, Issue 1, pp. 52-9, (2010) (PubMed).

    Bonnefond, Frugier, Touzé, Lorber, Florentz, Giegé, Sauter, Rudinger-Thirion: "Crystal structure of human mitochondrial tyrosyl-tRNA synthetase reveals common and idiosyncratic features." in: Structure (London, England : 1993), Vol. 15, Issue 11, pp. 1505-16, (2007) (PubMed).

  • Target

    YARS2 (Tyrosyl-tRNA Synthetase 2, Mitochondrial (YARS2))

    Andere Bezeichnung

    YARS2

    Hintergrund

    YARS2 catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr).

    Molekulargewicht

    53199

    NCBI Accession

    NP_001035526

    UniProt

    Q9Y2Z4
Sie sind hier:
Chat with us!